Phase 3 GiACTA Trial Results for TCZ in Giant Cell Arteritis
John H. Stone, MD, MPH, discusses results from a phase 3, double-blind, randomized, controlled trial evaluating the efficacy of tocilizumab for the treatment of giant cell arteritis.
John H. Stone, MD, MPH, discusses results from a phase 3, double-blind, randomized, controlled trial evaluating the efficacy of tocilizumab for the treatment of giant cell arteritis.
Researchers suggest that relapsing MPA and GPA and increased BMI were associated with increased glucocorticoid exposure following induction of remission.
Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.
Tocilizumab (Actemra®,Genentech) is the first treatment proposed for giant cell arthritis in 50 years.
Distinctive presentations, histopathology, and therapeutic response in both KD and KLS suggest a common etiology.
Retrospectively acquired population-based data suggest that the incidence of VTE, stroke and TIA was similar in patients with GCA compared to those who did not have GCA.
Low IgG and B cell counts were associated with infection and vaccine response among patients with systemic vasculitis in stable remission.
Rheumatology Advisor speaks with John Stone, MD, MPH, Edward Fox Chair in Medicine at Massachusetts General Hospital who is the lead investigator of a phase III, double-blind, randomized trial evaluating the safety and efficacy of tocilizumab for giant cell arteritis
Measuring IgG levels and B cell counts may identify high infection risk and help clinicians balance the risk of immunosuppression side effects and disease activity in patients with systemic vasculitis.
Study assesses long-term outcomes associated with Churg-Strauss syndrome and provides insights on how to better care for these patients.